Navigation Links
Gene Network Sciences Announces Broad Cancer Collaboration With UCSF and Initial Results
Date:5/27/2009

CAMBRIDGE, Mass., May 27 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced that it has entered into a research collaboration with the University of California San Francisco Cancer Center (UCSF) aimed at accelerating cancer research and drug development across several therapeutic areas. This collaboration will combine the clinical and research oncology expertise of UCSF with the computational expertise and supercomputer-driven REFS(TM) platform of GNS. Financial terms of the agreement were not disclosed.

GNS and UCSF have utilized REFS(TM) to discover and validate novel mediators of the cell cycle transition, which is a critical determinant of the rate of cancer cell proliferation and tumor growth. These results were presented by UCSF researcher Dr. Rina Gendelman, a post-doctoral fellow in Dr. W. Michael Korn's laboratory, at the American Association for Cancer Research 2009 meeting on April 18-22 in Denver, during which Dr. Gendelman received an AACR-Susan G. Komen Scholar-in-Training Award. GNS and prominent UCSF investigators Dr. Joe Gray, Dr. Frank McCormick, and Dr. W. Michael Korn will continue the collaboration through a number of additional projects.

Dr. Korn, who is an Associate Professor at UCSF, will lead the UCSF-GNS research partnership.

The parties will continue with research to elucidate the RAS-MAPK and PI3K cancer pathways, pathways critical for initiation and progression of many cancers, by building models of breast, pancreatic, and esophageal cancer based on data from ongoing research at UCSF using the REFS(TM) platform and simulation of these models. The discoveries from the ongoing research are expected to include potential novel drug targets in those cancer types.

"GNS is excited to be working with UCSF, a world-class research and clinical institution, to tackle key current issues in cancer research," said Dr. Iya Khalil, Executive Vice President and co-founder of GNS. "Our collaborative work with UCSF is one of several examples of GNS's applying our supercomputer-driven REFS(TM) platform to accelerate better treatments for patients with cancer."

About Gene Network Sciences

Gene Network Sciences (http://www.gnsbiotech.com/) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data. Based in Cambridge, Massachusetts, and Ithaca, New York, GNS uses its REFS(TM) technology in pharmaceutical and clinical settings to rapidly turn combinations of genetic, genomic, and clinical measurements into models of disease progression and drug response. These models are then simulated to discover both new targets for drug intervention and genetic markers of drug response that allow patients who will respond to a given drug treatment to be matched to a particular clinical trial. By discovering how and why specific sets of genes and drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.

About UCSF

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

UC Disclaimer

The information stated above was prepared by Gene Network Sciences, Inc., to report the outcome of research involving its product and reflects solely the opinion of GNS. Nothing in this statement shall be construed to imply any support or endorsement of GNS, or any of its products, by The Regents of the University of California, its officers, agents and employees.


'/>"/>
SOURCE Gene Network Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharma and Biotech Companies Plug into Singapores Integrated Research Network
2. HealthCore Responds to Need for Real-world Health Outcomes Information on Drugs and Devices with Physician Network and Prospective Effectiveness Research
3. Healthy Advice Networks Achieves Strong Growth Despite Challenging Economy
4. Chimerix Joins International Network of Organizations to Cure Malaria
5. Prime Health Network and Its Patients Thrive in Tough Economic Times on the InstaMed Network
6. NeoStem Expands Stem Cell Collection Center Network Into New Jersey Led by Leading Plastic Surgeon and Anti-Aging Authority
7. Agencies Unite to Launch Donor Network Alliance: First-Ever Web-Based Collective of Egg Donor Candidates
8. Gene Network Sciences Announces Michael Gilman as Board Member
9. UKs Institute of Cancer Research and Silicon Graphics Establish Long-Term Alliance to Design and Outfit World-Class Network Biology Lab
10. Yongye Biotechnology International to Expand its Network of Branded Stores
11. PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):